Cagrilintide
Long-acting amylin weight peptide
Also known as Cagri, the CagriSema partner
- Evidence grade
- BHuman trials, not approved for this useScale
- Half-life
- About 1 week
- Schedule
- Once weekly, subcutaneous
- Maintenance amount
- 2.40 mg
- Vial sizes sold
- 5 mg, 10 mg
Where a value is not established in people, this table says so rather than filling the box.
Cagrilintide is a long-acting analog of amylin, a hormone the pancreas releases alongside insulin. It is studied mainly as a weight-management peptide, most often co-dosed with semaglutide in the combination called CagriSema.
It activates amylin and calcitonin receptors that signal fullness, slow gastric emptying and reduce food intake. Amylin acts on hindbrain and hypothalamic circuits that complement GLP-1 signaling, which is why it is paired with semaglutide. A lipidation lets it bind albumin for once-weekly dosing. Human trials show added weight loss when combined with a GLP-1 agonist.
Human phase 1 through phase 3 trial data exists, mostly co-dosed with semaglutide; not yet approved as a standalone.
- Studied for additional body-weight reduction, especially alongside semaglutide
- May increase fullness and reduce food intake through amylin signaling
- Studied for improved glucose control when combined with a GLP-1 agonist
- May complement GLP-1 drugs through a separate appetite pathway
- Nausea, vomiting and other gastrointestinal effects, worse during dose increases
- Injection-site reactions
- Possible low blood sugar when stacked with other glucose-lowering agents
- Appetite suppression that can reduce nutritional intake
A summary of the research, not medical advice. Individual benefits and risks vary, and for some of these compounds the human evidence is still early.
In the REDEFINE 1 trial, cagrilintide alone produced a mean 11.5 percent body weight reduction at 68 weeks, versus roughly 3 to 4 percent on placebo. It is most often studied paired with semaglutide, where the combination reported a substantially larger result.
Read the full timeline →Drawn from published trial data and how the research community commonly describes this stretch. Not a fixed schedule and not medical advice.
Once weekly, subcutaneous. For research reference only, not medical advice.
| Phase | Amount |
|---|---|
| Weeks 1–4 | 0.3 mg |
| Weeks 5–8 | 0.6 mg |
| Weeks 9–12 | 1.2 mg |
| Weeks 13+ | 2.4 mg |
Titrated slowly, most often co-dosed with semaglutide as CagriSema. Research amounts only.
Higher amounts, more injections. As the weekly total climbs, it is commonly divided into two or more injections across the week, which keeps each shot small and easier to tolerate.
A rough shopping estimate at the maintenance amount. Your real needs shift with your dose and titration.
| Item | 12-week plan | 18-week plan | 24-week plan |
|---|---|---|---|
| Peptide vials (5 mg) | 2 | 5 | 8 |
| Insulin syringes (U-100) | 12 | 18 | 24 |
| Bacteriostatic water (10 mL) | 1 | 1 | 2 |
| Alcohol swabs (100-count box) | 1 | 1 | 1 |
Lyophilized: Keep the sealed powder cold and dark, near -20 °C, dry and out of light.
Reconstituted: Refrigerate the mixed vial at 2 to 8 °C, use within a few weeks and avoid freeze and thaw.
Let a cold vial reach room temperature before you open it, so it takes on less condensation.
How strong is the evidence for Cagrilintide?
We grade it B on a four-point scale. Phase 1 through phase 3 data, mostly co-dosed with semaglutide. Not approved on its own.
What is the half-life of Cagrilintide?
About 1 week. That is the figure the reported dosing frequency follows from.
What amount of Cagrilintide is used in the research?
Weeks 1–4: 0.3 mg. Weeks 5–8: 0.6 mg. Weeks 9–12: 1.2 mg. Weeks 13+: 2.4 mg. Titrated slowly, most often co-dosed with semaglutide as CagriSema. Research amounts only.
How is Cagrilintide stored once reconstituted?
Refrigerate the mixed vial at 2 to 8 °C, use within a few weeks and avoid freeze and thaw.